Holaira says it raised a $42 million Series D round to back a clinical trial of its lung denervation technology.
Holaira said it raised a $42 million Series D round it plans to use for what it claims as the 1st randomized lung denervation trial with a sham control arm.
Minneapolis-based Holaira said the round was led by Vertex Venture Holdings and included 2 unnamed strategic investors, Windham Venture Partners and existing backers Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners and Versant Ventures.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1hkM1cT
Cap comentari:
Publica un comentari a l'entrada